← Back to front page
United States · Exchanges & live quotes · Nasdaq

Johnson & Johnson Set To Buy Ollin Biosciences For Up To $3.4 Bln: Report

Published by Nasdaq · United States 1 h ago

Detailed summary

(RTTNews) - Johnson & Johnson (JNJ) is close to acquiring eye disease drug developer Ollin Biosciences in a deal valued at up to $3.4 billion, according to a Financial Times…

Read the full article on Nasdaq Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.nasdaq.com)

Also worth reading